Call for Papers: JFDA Special Issue on Drug Resilience
Subject: Call for Papers: JFDA Special Issue on “Advancing Global Drug Resilience: Regulatory Science, Supply Chain Integrity, and Technological Innovation”
Dear Colleagues,
On behalf of the Editorial Board of the Journal of Food and Drug Analysis (JFDA), we are pleased to announce the launch of a forthcoming Special Issue dedicated to “Advancing Global Drug Resilience: Regulatory Science, Supply Chain Integrity, and Technological Innovation.” We cordially invite researchers, clinicians, regulatory experts, and industry leaders to contribute original research articles, comprehensive reviews, and perspective papers to this timely issue.
Rationale and Scope
In an era marked by geopolitical shifts, climate uncertainties, and public health emergencies, ensuring a continuous, secure, and resilient supply of critical medicines has become a cornerstone of national security and public health sustainability. Drug resilience encompasses not only the robustness of pharmaceutical manufacturing and supply chains but also the agility of regulatory frameworks to adapt to emerging crises and therapeutic innovations.
This Special Issue aims to provide a high-profile platform for cutting-edge research and critical discussions on safeguarding pharmaceutical ecosystems. We welcome submissions that address theoretical frameworks, empirical studies, and technological advancements across the spectrum of drug resilience, regulatory science, and medical products.
Key topics of interest include, but are not limited to:
Strategic Pharmaceutical Readiness: Frameworks, national monitoring systems, and policy metrics for mitigating drug shortages and securing essential medicines.
Regulatory Science & Digital Transformation: The role of AI-enabled risk detection, e-Submission efficiencies, and modernized regulatory pathways in accelerating access to critical therapies.
Supply Chain Integrity & Vulnerability Assessment: Data-driven models, predictive analytics, and proactive surveillance mechanisms for pharmaceutical supply chains.
Innovation in Medical Products & Advanced Therapeutics: Regulatory and manufacturing resilience concerning cutting-edge biomedical innovations, including regenerative medicine and advanced medical devices.
Cross-Domain Synergy: Public-private partnerships, international regulatory convergence, and talent cultivation strategies tailored for resilient biopharmaceutical ecosystems.
Submission Guidelines
All manuscripts must be submitted online via the JFDA Online Submission System. (https://www.editorialmanager.com/jfda/default.aspx)
Manuscript Preparation: Submissions must adhere to the standard formatting, ethical guidelines, and “Aims & Scope” of the Journal of Food and Drug Analysis. Please select the special issue title “Advancing Global Drug Resilience” during the submission process.
AI Use Declaration: In alignment with JFDA’s commitment to academic integrity and technological transparency, authors utilizing generative AI or AI-assisted technologies in the writing or data analysis process are required to include an explicit AI Use Declaration in their submission.
Review Process: All submissions will undergo a rigorous, independent peer-review process coordinated by the Editorial Board to ensure the highest standards of scientific quality and regulatory relevance.
Important Dates
Manuscript Submission Deadline: December 31, 2026
Expected Publication Date: March 15, 2027 (Accepted articles will be published online ahead of print)
For any inquiries regarding the suitability of potential manuscripts or the submission process, please contact the JFDA Editorial Office through the submission portal.
We look forward to receiving your impactful work and collectively shaping the future of global pharmaceutical resilience.
Sincerely,
The Editorial Board
Journal of Food and Drug Analysis (JFDA)
